Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions.

[2greys]

For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of participants in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

Among previously untreated patients, the objective response rate (ORR) was 85%, and those receiving at least prior platinum-based chemotherapy had an ORR of 64%. For patients with brain metastases, there was a 91% ORR in the brain.

Results from LIBRETTO-001, published today in the New England Journal of Medicine, led to the approval of selpercatinib in May by the Food and Drug Administration for RET-altered lung and thyroid cancers.

mdanderson.org/newsroom/lun...